What does this research mean for the field?

Persistence with GLP-1-based therapies among adults with obesity and type 2 diabetes is highly variable and often falls below 60% within the first one to two years, primarily due to adverse effects and demographic factors. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate how treatment persistence is defined, measure real-world continuation and discontinuation rates, and identify factors and supportive strategies affecting GLP-1 therapy in adults with coexisting obesity and type 2 diabetes.

August 16, 2026Current Diabetes ReportsOpen Access

Persistence in GLP-1–Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants

View Full Paper

Ask AI

Bookmark

Authors

TWTzu Wang OSOlayinka O. Shiyanbola

Discussion

Member takes

Overview

Narrative review reveals that GLP-1 persistence often falls below 60% at two years in adults with obesity and type 2 diabetes, highlighting a need for better routine supportive care.

Key Points

To evaluate how treatment persistence is defined, measure real-world continuation and discontinuation rates, and identify factors and supportive strategies affecting GLP-1 therapy in adults with coexisting obesity and type 2 diabetes.
Reviewed seven published studies with follow-up periods ranging from 6 months to 2 years.
Synthesized findings on refill-gap criteria, therapy continuation rates, treatment interruptions, and determinants of persistence.
Persistence rates steadily declined over time, frequently dropping below 60% between 12 and 24 months, with discontinuation reaching 64.1% at 2 years in one large cohort.
Key factors influencing continuation included patient age, income level, gastrointestinal adverse effects, degree of weight reduction, body mass index, specific drug agent, formulation, and dosing schedule.
Only two studies documented patient-reported reasons for stopping therapy, with adverse effects being the most common, and none evaluated structured behavioral support interventions.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a817a01f2fb91fc834ad806 https://doi.org/10.1007/s11892-026-01639-0

View Full Paper

Ask AI

Bookmark

August 16, 2026Current Diabetes ReportsOpen Access

Persistence in GLP-1–Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants

View Full Paper

Ask AI

Bookmark

Authors

TWTzu Wang OSOlayinka O. Shiyanbola

Discussion

Member takes

Overview

Narrative review reveals that GLP-1 persistence often falls below 60% at two years in adults with obesity and type 2 diabetes, highlighting a need for better routine supportive care.

Key Points

To evaluate how treatment persistence is defined, measure real-world continuation and discontinuation rates, and identify factors and supportive strategies affecting GLP-1 therapy in adults with coexisting obesity and type 2 diabetes.
Reviewed seven published studies with follow-up periods ranging from 6 months to 2 years.
Synthesized findings on refill-gap criteria, therapy continuation rates, treatment interruptions, and determinants of persistence.
Persistence rates steadily declined over time, frequently dropping below 60% between 12 and 24 months, with discontinuation reaching 64.1% at 2 years in one large cohort.
Key factors influencing continuation included patient age, income level, gastrointestinal adverse effects, degree of weight reduction, body mass index, specific drug agent, formulation, and dosing schedule.
Only two studies documented patient-reported reasons for stopping therapy, with adverse effects being the most common, and none evaluated structured behavioral support interventions.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a817a01f2fb91fc834ad806 https://doi.org/10.1007/s11892-026-01639-0

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark